Sugi Predict

Sugi Predict / Compounds / SCHEMBL1625810

SCHEMBL1625810

SCHEMBL1625810

O=[N+]([O-])c1cc2c(cc1Nc1ccc(CCO)cc1)OCO2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ KMT2A Q03164 9/20 0.45
▸ MEN1 O00255 8/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ PABPC1 P11940 1/20 0.43
▸ EIF4H Q15056 1/20 0.43
▸ POLB P06746 2/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624830 0.93 KMT2A (0.43) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1624206 0.80 MAPT (0.52) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1625292 0.80 MERTK (0.52) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL1624955 0.79 MERTK (0.61) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL1625649 0.78 TAAR1 (0.39) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1625757 0.77 KMT2A (0.64) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1627016 0.76 LMNA (0.56) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1624234 0.76 FBP1 (0.47) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL1624567 0.76 L3MBTL1 (0.50) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL1624580 0.76 L3MBTL1 (0.64) MAPTALDH1A1KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928119-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2011-04-19 — — US disclosed
US-7479564-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents RAQUALIA PHARMA INC. (JP) 2009-01-20 — — US disclosed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 — — US disclosed
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PFIZER INC. 2007-03-22 — — US disclosed
US-7148234-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2006-12-12 — — US disclosed
US-7141580-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PFIZER INC. (US) 2006-11-28 — — US disclosed
EP-1666480-A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. PFIZER PHARMACEUTICALS INC. (JP) 2006-06-07 — — EP disclosed
EP-1326864-B1 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMA (JP) 2006-03-15 — — EP disclosed
EP-1499305-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES Pfizer Japan Inc. (JP) 2005-01-26 — — EP disclosed
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2004-09-16 — — US disclosed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 — — US disclosed
CN-1477960-A EPA receptor inhibitors to treat rheumatoid arthritis — 2004-02-25 — — CN disclosed
CN-1476448-A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ������ҩ�����޹�˾ 2004-02-18 — — CN disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 — — US disclosed
WO-2003086371-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES PFIZER JAPAN INC. (JP) 2003-10-23 — — WO disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 — — US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 MAPT 3250/4885ALDH1A1 588/4885KMT2A 2917/4885
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PTGER4, PTGER1, IL6 MAPT 4402/4885ALDH1A1 1858/4885KMT2A 4355/4885
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 MAPT 4402/4885ALDH1A1 1858/4885KMT2A 4355/4885
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 MAPT 3288/4885ALDH1A1 632/4885KMT2A 2967/4885
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PTGS1, PTGS2, PTGES MAPT 3806/4885ALDH1A1 798/4885KMT2A 3274/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 MAPT 4854/4885ALDH1A1 1286/4885KMT2A 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.